| 000 | 01407 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250518010624.0 | ||
| 264 | 0 | _c20190925 | |
| 008 | 201909s 0 0 eng d | ||
| 022 | _a2040-2058 | ||
| 024 | 7 |
_a10.3851/IMP3245 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aForton, Daniel | |
| 245 | 0 | 0 |
_aExpert opinion on managing chronic HCV in patients with neuropsychiatric manifestations. _h[electronic resource] |
| 260 |
_bAntiviral therapy _c2018 |
||
| 300 |
_a47-55 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntiviral Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aCognitive Dysfunction _xcomplications |
| 650 | 0 | 4 |
_aDepression _xcomplications |
| 650 | 0 | 4 | _aDisease Management |
| 650 | 0 | 4 |
_aFatigue _xcomplications |
| 650 | 0 | 4 |
_aHepacivirus _xdrug effects |
| 650 | 0 | 4 |
_aHepatitis C, Chronic _xcomplications |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aNeuroprotective Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aNootropic Agents _xtherapeutic use |
| 650 | 0 | 4 |
_aParkinson Disease _xcomplications |
| 650 | 0 | 4 | _aPractice Guidelines as Topic |
| 650 | 0 | 4 |
_aQuality of Life _xpsychology |
| 650 | 0 | 4 | _aRisk Factors |
| 700 | 1 | _aWeissenborn, Karin | |
| 700 | 1 | _aBondin, Mark | |
| 700 | 1 | _aCacoub, Patrice | |
| 773 | 0 |
_tAntiviral therapy _gvol. 23 _gno. Suppl 2 _gp. 47-55 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3851/IMP3245 _zAvailable from publisher's website |
| 999 |
_c29066290 _d29066290 |
||